AG0302-COVID-19 is a COVID-19 vaccine candidate developed by AnGes Inc.[3][4] This candidate followed a previous one called AG0301-COVID-19.[5]
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | DNA |
| Clinical data | |
| Routes of administration | Intramuscular, Intradermal[1] |
| Identifiers | |
| CAS Number | |
References
edit- ^ "Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)". clinicaltrials.gov. United States National Library of Medicine. Archived from the original on 9 August 2021. Retrieved 6 October 2021.
- ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
- ^ "Study of COVID-19 DNA Vaccine (AG0302-COVID19)". clinicaltrials.gov. United States National Library of Medicine. 3 December 2020. Retrieved 11 March 2021.
- ^ "Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)". clinicaltrials.gov. United States National Library of Medicine. Archived from the original on 8 December 2020. Retrieved 11 March 2021.
- ^ "Study of COVID-19 DNA Vaccine (AG0301-COVID19)". ClinicalTrials.gov. United States National Library of Medicine. 9 July 2020. NCT04463472. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
Scholia has a profile for AG0302-COVID‑19 (Q106514993).
.svg){kind=small}
.png){kind=small} | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |